Antony C. Mattessich

Antony C. Mattessich (chief executive) discloses dealings in 2 companies, chiefly Ocular Therapeutix, Inc and Aura Biosciences, Inc. We count 15 filings; the first trade dates from 12 December 2017 and the latest from 11 June 2026.

Market trades split into 6 purchases (€436k) and 3 sales (€250k). Netting one side against the other leaves €187k of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 6 share grants.

In size, the median ticket on the buying side is €84k. Of 6 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

On 15 June 2026 came the latest disclosure, a share grant in Aura Biosciences, Inc. The clock since the last published purchase (5 September 2023) now reads 1,145 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.